ALLENA PHARMACEUTICALS INC (ALNA) Stock Price, Quote, News and Overview
NASDAQ:ALNA - Nasdaq - US0181191075 - Common Stock - Currency: USD
ALNA Quote, Performance and Key Statistics
0.075
+0 (+3.16%)
The current stock price of ALNA is 0.075 USD. In the past month the price decreased by -41.36%. In the past year, price decreased by -92.72%.
ALNA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.61 | 337.52B | ||
| AMGN | AMGEN INC | 14.22 | 158.74B | ||
| GILD | GILEAD SCIENCES INC | 14.21 | 136.81B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 116.96B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.94 | 57.14B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 40.16B | ||
| ARGX | ARGENX SE - ADR | 100.5 | 35.29B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.89 | 29.17B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.62B | ||
| NTRA | NATERA INC | N/A | 22.58B | ||
| BIIB | BIOGEN INC | 8.26 | 19.14B | ||
| INSM | INSMED INC | N/A | 17.98B |
Related stock screener links
About ALNA
Company Profile
Allena Pharmaceuticals, Inc. engages in the development, discovery, and commercialization of oral enzyme therapeutics to treat patients with kidney disorders. The company is headquartered in Sudbury, Massachusetts and currently employs 21 full-time employees. The company went IPO on 2017-11-02. The firm is focused on metabolic disorders that result in excess accumulation of certain metabolites that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease (CKD) and end-stage renal disease (ESRD). The Company’s lead product candidate, reloxaliase, is an oral enzyme therapeutic developing for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate (UOx) levels and commonly associated with kidney stones, CKD and ESRD. Its second product candidate, ALLN-346, is an orally administered, novel, urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced CKD. The firm is conducting two Phase IIa studies for ALLN-346.
Company Info
ALLENA PHARMACEUTICALS INC
142 -F North Road, Suite 150
Sudbury MASSACHUSETTS 02462 US
CEO: Louis Brenner
Employees: 21
Phone: 16174674577.0
ALLENA PHARMACEUTICALS INC / ALNA FAQ
What is the stock price of ALLENA PHARMACEUTICALS INC today?
The current stock price of ALNA is 0.075 USD. The price increased by 3.16% in the last trading session.
What is the ticker symbol for ALLENA PHARMACEUTICALS INC stock?
The exchange symbol of ALLENA PHARMACEUTICALS INC is ALNA and it is listed on the Nasdaq exchange.
On which exchange is ALNA stock listed?
ALNA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ALLENA PHARMACEUTICALS INC stock?
7 analysts have analysed ALNA and the average price target is 4.08 USD. This implies a price increase of 5340% is expected in the next year compared to the current price of 0.075. Check the ALLENA PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ALLENA PHARMACEUTICALS INC worth?
ALLENA PHARMACEUTICALS INC (ALNA) has a market capitalization of 8.08M USD. This makes ALNA a Nano Cap stock.
How many employees does ALLENA PHARMACEUTICALS INC have?
ALLENA PHARMACEUTICALS INC (ALNA) currently has 21 employees.
What are the support and resistance levels for ALLENA PHARMACEUTICALS INC (ALNA) stock?
ALLENA PHARMACEUTICALS INC (ALNA) has a resistance level at 0.1. Check the full technical report for a detailed analysis of ALNA support and resistance levels.
Should I buy ALLENA PHARMACEUTICALS INC (ALNA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ALNA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ALNA, evaluating the profitability, health, valuation and growth aspects
- ALLENA PHARMACEUTICALS INC (ALNA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ALLENA PHARMACEUTICALS INC (ALNA) Sales and EPS estimates to see what analysts future expectations are.
- ALLENA PHARMACEUTICALS INC (ALNA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ALLENA PHARMACEUTICALS INC (ALNA) Insider and Institutional Ownership to learn about the owners and their transactions.
- ALLENA PHARMACEUTICALS INC (ALNA) Stock Chart to make your own analysis
- ALLENA PHARMACEUTICALS INC (ALNA) Latest news and press-releases to stay up to date.
Does ALLENA PHARMACEUTICALS INC (ALNA) stock pay dividends?
ALNA does not pay a dividend.
When does ALLENA PHARMACEUTICALS INC (ALNA) report earnings?
ALLENA PHARMACEUTICALS INC (ALNA) will report earnings on 2022-11-08.
What is the Price/Earnings (PE) ratio of ALLENA PHARMACEUTICALS INC (ALNA)?
ALLENA PHARMACEUTICALS INC (ALNA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.49).
ALNA Technical Analysis
ALNA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ALNA. Both the profitability and financial health of ALNA have multiple concerns.
ALNA Financial Highlights
Over the last trailing twelve months ALNA reported a non-GAAP Earnings per Share(EPS) of -0.49. The EPS increased by 46.15% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -243.13% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
ALNA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 46% to ALNA. The Buy consensus is the average rating of analysts ratings from 7 analysts.